1. Propranolol and folic acid absorption were studied separately in healthy subjects, noncoeliac patients and patients with treated and untreated coeliac disease.
Introduction
According to the pH-partition hypothesis [ 1 1, the absorption of dissociable drugs is influenced by the degree of ionization at the pH in the intestinal lumen, the un-ionized form being preferentially absorbed. As this concept did not explain the satisfactory absorption of certain acidic substances, the authors [ l ] postulated an area of higher acidity at the surface of the small intestinal cells, an 'acid microclimate' with a 'virtual pH' of 5.3. This surface pH has been measured with pH-electrodes [21 and found to be 5.9 in biopsy specimens from human intestine. However, in coeliac disease, values for surface pH were considerably less acid. Such a reduction in the acidity of the microclimate should reduce the absorption of acidic drugs and enhance the absorption of basic substances. Two substances which seem to behave according to this hypothesis are folic acid and the basic drug propranolol (pK, = 9.45). Folic acid malabsorption in coeliac disease is well known and elevations of mean plasma propranolol concentrations have also been found in this disease after oral dosage [3]. The present study is concerned with the relationship between the measured surface pH and the absorption of these two substances.
Methods

Groups investigated
(1) Healthy subjects with no clinical signs of illness: four females and six males, age 21-39 years, for the propranolol studies; three females and seven males, age 2 1-3 1 years, for the folate studies.
(2) Miscellaneous non-coeliac patients whose disorders included Crohn's disease, folate deficiency of unknown aetiology, irritable bowel syndrome, gall-stones and non-specific gastrointestinal symptoms: four females and two males, age 22-45 years, for the propranolol studies; two females and three males, age 20-45 years, for the folate studies.
(3) Patients with confirmed coeliac disease who had been treated with a gluten-free diet for more than 6 months and who had shown histological improvement on further jejunal biopsy: six females and four males, age 23-66 years, for the propranolol studies; three males and three females, age 23-57 years, for the folate studies.
(4) Patients with newly diagnosed coeliac disease, before any treatment. The diagnosis was confirmed histologically at the time of the investigation and by subsequent improvement on a gluten-free diet: five females and four males, age 11-57 years, for the propranolol studies; three males and three females, age 12-54 years, for the folate studies.
All subjects had normal values for haemoglobin concentration, leucocyte count, erythrocyte sedimentation rate, blood urea and electrolytes and had normal results from liverfunction tests, including serum albumin, globulin, seromucoids, bilirubin, alkaline phosphatase and aspartate aminotransferase. The study was approved by the Ethical Committee of the Central Birmingham Health District. Informed consent was obtained from all participants.
Jejunal surface pH measurements
Jejunal surface pH was measured in vitro in jejunal biopsy specimens obtained with a suction biopsy capsule [41 from all subjects after an overnight fast. The technique has been described elsewhere in detail [21 and was modified only in that a commercially available Pye M405 oesophageal electrode was adapted by the manufacturers and the pH recorded with a Pye-Unicam 9409 digital pH meter.
Drug absorption studies
Propranolol. After the patient had fasted overnight, a single 40 mg tablet of propranolol (Inderal, ICI) was given by mouth with approximately 50 ml of water. Venous blood samples (10 ml) were obtained from an indwelling cannula kept patent with a slow infusion of sodium chloride solution (154 mmol/l: saline) at zero, f, 
Pharmacokinetic analysis of data
The plasma concentration curves were analysed in terms of a one-compartment model with two differential equations describing an absorption and an elimination process, whose solution is:
where FD/V is the bioavailability constant, K, is apparent absorption rate constant, K, is apparent elimination rate constant, t* = (real time -lag time). The curve-fitting procedure involved computing the best least-squares fit through the mean data for each group rather than the data for each individual subject. The rate constants associated with the two processes were estimated by graphical methods 181, as were the bioavailability function and the lag time. As the alternative program could not process data where no peak of absorption was available, the first procedure was preferred in order to maintain internal comparison.
Results
Jejunal surface pH studies
Jejunal surface pH was significantly elevated (P < 0.001) in both the treated and untreated coeliac groups (Table l) , when compared with pH in the healthy controls. These results, obtained with a commercially obtained electrode, are similar to those obtained in another study [21 with other types of electrodes made in this laboratory.
Propranolol absorption studies
Plasma propranolol levels were significantly higher in the treated and untreated coeliac groups than in the group of healthy subjects, from If to 8 h ( Fig. 1 ). The mean plasma propranolol level in the untreated coeliac group tended to be higher than in the treated group of patients but the difference did not reach statistical significance. Neither the treated nor untreated coeliac groups differed in plasma propranolol concentration from the miscellaneous group. Among 34 patients where surface pH and propranolol absorption was studied (ten healthy controls, nine untreated coeliac patients, ten treated coeliac patients and five others), there was a significant association between jejunal surface pH and plasma propranolol levels at lf h (r = 0.35, P < 0-OS), 2 h (r = 0.368, P < 0.05) and 4 h (r = 0.372, P < 0.05).
Folic acid absorption studies
Although initial serum folate levels did not differ between the groups, significantly lower serum folate levels after a 5 mg oral dose are found in the treated and untreated coeliac patients than in the healthy controls (Fig. 2) . The value in the untreated group was also significantly lower than in the miscellaneous group. In 31 subjects (ten healthy controls, six untreated and six treated coeliac patients, three patients with Crohn's disease and six others) there was a Tables 82/2A and 82/28 respectively with the Librarian, the Royal Society of Medicine, (1 Wimpole Street, London W 1M 8AE), who will issue copies on request. 6.23 f 0.04'"' Series B n = 10 n = 5 n = 6 n = 6 n = 12 significant inverse association between jejunal surface pH and the serum folate levels at 1, If and 2 h and at peak values (all r < -0-472, P <
0.01).
Pharmacokinetic analysis of absorption curves
The absorption curves were analysed in terms of a one-compartment model ( Table 2) derive absorption and elimination constants for the process, lag times for the onset of absorption and estimates of the bioavailability function (FD/V = systemically available dose/ compartmental volume of distribution). Lag times, of the order of 17-25 min, showed no consistent trend for the two drugs within the studied groups. The bioavailability function was lower for both drugs for the untreated coeliac groups, significantly so (P < 0.001) for propranolol. There was a significant decrease in the propranolol elimination rate constant for both the treated and untreated coeliac groups and a marginal increase in the folate elimination rate constant in the treated coeliac group. The folate absorption rate constant was depressed (P < 0.02) in the untreated coeliac group and the treated group constant was less than that of the miscellaneous group. In contrast, when compared with the healthy subjects, the absorption rate constant of propranolol was elevated in the treated (P < 0.05) and untreated (P < 0.01) coeliac groups but not in the miscellaneous group. With a similar program [lo] used for estimating the propranolol rate constants, much the same values were obtained although this program could not process the folate data. The derived rate constants for absorption correlated significantly (Fig. 3) with the measured surface pH in that the folate constants decreased and those for propranolol increased with an increase in surface pH.
Discussion
The disposition in plasma of an orally administered drug is a complicated process, potentially affected by gastric emptying, hepatic and renal clearance, plasma protein binding and the rate and degree of absorption. Additionally, P-adrenoceptor-blocking drugs such as propranolol affect their own disposition by reducing hepatic blood flow [ l l ] . The changes in the plasma concentrations of propranolol and folic acid found in this study may be due to a combination of some of these factors, and it is unlikely that any single explanation is exclusive of other interpretations.
The rate of absorption of drugs may be affected by changes in gastric emptying. In coeliac disease, both increased and decreased motility have been claimed [12-151 and, in the present study, lag times, which probably reflect the rate of gastric emptying, showed no definite trend ( Table 2) . Such contradictory findings make it unlikely that this factor is involved in consistently altering plasma drug Concentrations in coeliac disease, especially as propranolol levels were raised, whereas those of folic acid were lowered.
Propranolol is almost entirely eliminated by metabolism in the liver, and plasma concentrations of this drug are known to be raised after oral administration to patients with hepatic cirrhosis [ 161. Increased levels of serum aspartate aminotransferase and alanine aminotransferase have been reported in 55% of one series of coeliac patients [ 171, indicating some measure of hepatic damage, but none of the subjects in the present study had any clinical or biochemical evidence of liver disease. Furthermore, this would not explain the reduced plasma levels of folic acid. Reduced liver blood flow is known to increase systemic plasma concentrations of propranolol, but no evidence of this has been reported in coeliac disease.
Raised plasma propranolol concentrations have been found in patients with inflammatory disease and a raised erythrocyte sedimentation rate [18] and correlate significantly with the serum level of a,-acid glycoprotein [ 191 to which this drug binds [20, 211. In the present investigation, however, all subjects had erythrocyte sedimentation rates and serum a,-acid glycoprotein concentrations within normal limits.
The most striking changes to emerge from the pharmacokinetic analysis of the data obtained from this study are the increase in the absorption rate constant for propranolol, and the decrease in the same constant for folic acid, in coeliac disease. These differences would be accentuated if the compartmental volume changes that may occur in coeliac disease are taken into consideration (see the Appendix). Propranolol is a basic drug, which according to the pH-partition hypothesis [ 1 I would be more easily absorbed at the coeliac microclimate pH (6.37), as less of it would be ionized. Whether the mechanism of folic acid absorption is by simple diffusion [22] or by a pH-dependent saturable mechanism of transport for the undissociated form [231, it is clear that an elevated surface pH should decrease absorption. The choice of phosphate buffer meant that the measurement of surface pH was made in the absence of bicarbonate, an anion which may stimulate certain aspects of jejunal function 1241. However, in rat gut in vitro, surface pH values were similar in both phosphate and bicarbonate buffers [251, and resembled those found in the rat jejunum in viuo (M. L. Lucas, unpublished work) , provided that glucose (10 mmol/l) was included in the buffer used in vitro. In rat jejunum in vivo, surface pH values of 6-23 ? 0.1 [71 and 6-10 f 0-1 [7] have been found in bicarbonate and phosphate buffers respectively, although no dependence on buffer glucose was noted as adequate substrate was available via the intact blood supply. It thus seemed justified to extrapolate the present human data in vitro to the situation in vivo, and to use a phosphate buffer in the interests of stability.
Correlation can be shown between the log of the absorption rate constant and the jejunal surface pH for both drugs, an inverse relationship for folk acid. The fact that correlation of plasma drug levels with surface pH is modest, though significant at some times, probably reflects the multifactorial nature of drug disposition. Preliminary calculations have also been made of the fraction of undissociated drug (f) available at the measured surface pH values found in the various groups of subjects studied, even though no claim is made that these are the exact values to be found directly at the enterocyte membrane. In the case of propranolol with its single dissociable group, these were straightforward, but with folic acid the pK, values [261 of the a-and y-carboxyl groups and of the N-1 nitrogen had to be taken into account. Such a calculation shows (Fig. 4) that the apparent absorption rate constant (K ,) increases with the apparent fraction of undissociated or zwitterionic forms, thus supporting the hypothesis that it is the un-ionized form of a weak electrolyte that is preferentially absorbed.
Ideally, K , and f would be calculated for each subject. In practice this would involve calculation of the four disposition parameters from seven data points. Under these circumstances, convergence in the estimation procedure could be achieved only by the prior selection of subjectively chosen constraints, which necessarily vitiates any such best fit procedure. Consequently, an acceptable estimate of K , could be satisfactorily derived only from grouped data. These calculations, as well as the previously mentioned data, indicated that, in these particular instances, alterations of surface pH were correlated with changes in the rate of drug absorption.
There are other instances in the literature of 50 1
4.
10' x Fraction undiswciated ('%) FIG. 4. Relation of absorption rate constant ( K , ) to calculated fraction of undissociated drug. 1, Normal subjects; 2, miscellaneous non-coeliac group; 3, coeliac (gluten-free diet); 4, coeliac (normal diet); 0 , propranolol; 0 , folic acid. investigated the pharmacokinetics of the two acidic, lipid-soluble drugs, aspirin and indomethacin, which have pK, 3.5 and pK, 4.6 respectively. No significant differences were found between the areas under the plasma concentration-time curves or between the absorption rate constants of healthy subjects and coeliac patients for either drug, although the salicylate plasma levels were significantly raised in the coeliac patients at the first three sampling times. Thus it seems that factors such as changes in water solubility at different pH values, and lipid solubility, may also exert an effect on plasma drug concentrations. A factor which is less easily explained is the change in the elimination rate constants for both drugs, that for propranolol being decreased, and that for folic acid increased. It is known that (rt )-propranolol decreases liver blood flow and thus influences its own elimination [ l l l . If the drug is being absorbed more quickly in coeliac disease, higher concentrations may be delivered to the liver via the portal vein, and thus there will be a greater effect on blood flow and clearance than in normal subjects, even though liver function is normal. In the case of folic acid, the increase in elimination rate constant may be caused by an increase in the volume of distribution, or an increase in tissue avidity, which can occur in subjects who have been folate deficient.
Thus it is clear that the absorption step is not the only variable that determines subsequent levels of drug in plasma after an oral dose. In the present study, a group of non-coeliac patients with a variety of diseases, but with normal microclimate pH, histology and erythrocyte sedimentation rates, showed raised plasma propranolol levels, halfway between those in the coeliac and those in the control groups, and not significantly different from either. The absorption rate constants, however, were only negligibly raised compared with those of the controls, suggesting that it is mainly the rate of absorption of propranolol which is affected in coeliac disease. In a similar group of patients given folic acid, the non-significant depression in serum folate levels compared with the healthy subjects may again have been due to increased tissue uptake.
The results of the present study are consistent with the concept of an acid surface pH in the jejunum being a controlling influence in the rate of absorption of these drugs. At present it is impossible to rule out, on present grounds, effects of surface pH on absorption by means other than pH-partition: it is possible that changes in surface pH may alter the ionization state of a putative transport protein. Also it may be premature to state that changes in microclimate pH are relevant to all dissociable drugs. However, it would seem to be a factor that should be taken into account when considering changes in drug disposition in disease states.
